BCL11B
BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.
Overview
Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of haematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus. Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.94, animal model 0.46, genetic association 0.55, somatic mutation 0.86). IntOGen calls it a driver in 3 cohorts (3 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Glioblastoma Multiforme, Vulva/Vagina.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.
- 1 · What it is
BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals.
- 3 · How drugs use it
No product in this corpus aims at BCL11B yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:13222 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9C0K0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000127152 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: colorectal cancer 0.51, melanoma 0.52, non-Hodgkin lymphoma 0.56, skin cancer 0.56, breast cancer 0.52, lung cancer 0.50 (GraphQL API, CC0)); IntOGen BCL11B (driver in 3 cohorts (Act 3, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of haematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus. Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes. Tumour-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element. May also function in the P53-signalling pathway. Location: Nucleus (UniProt). Locus 14q32.2 (HGNC).
- Vulvar cancer: IntOGen driver in 1 cohort (VULVA)
- Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Leukaemia: Open Targets association 0.53 with leukaemia (MONDO_0005059)
- Breast cancer: Open Targets association 0.52 with breast cancer (MONDO_0007254)
- Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"BCL11B" OR ABSTRACT:"BCL11B" OR TITLE:"BCL11 transcription factor B" OR ABSTRACT:"BCL11 transcription factor B" OR TITLE:"B-cell lymphoma/leukemia 11B" OR ABSTRACT:"B-cell lymphoma/leukemia 11B" OR TITLE:"CTIP-2" OR ABSTRACT:"CTIP-2" OR TITLE:"CTIP2" OR ABSTRACT:"CTIP2" OR TITLE:"hRIT1-alpha" OR ABSTRACT:"hRIT1-alpha") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCL11B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPAX5
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetSND1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetTBL1XR1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetBCL6
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetTP63
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetRUNX1T1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTNFRSF14
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.